Grown Rogue International (GRUSF) Non Operating Investment Income (2011 - 2025)
Grown Rogue International (GRUSF) posted quarterly Non Operating Investment Income of $234.4 billion for Q3 2025, up 148.05% year-over-year from $94.5 billion in Q3 2024, and up 294417622.63% quarter-over-quarter from $79627.0 in Q1 2025.
Grown Rogue International (GRUSF) Non Operating Investment Income (2011 - 2025) Analysis & Trends
Grown Rogue International's Non Operating Investment Income history runs 10 years deep, the most recent figure standing at $234.4 billion for Q3 2025.
- In Q3 2025, Non Operating Investment Income rose 148.05% year-over-year to $234.4 billion; the TTM figure through Sep 2025 stood at $234.4 billion (up 148.05% YoY), while the FY2024 annual figure was $50057.0, down 42.92% from the prior year.
- Non Operating Investment Income for Q3 2025 stood at $234.4 billion, up from $79627.0 in the prior quarter.
- The five-year high for Non Operating Investment Income was $487.9 billion in Q4 2024, with the low at -$487.9 billion in Q3 2024.
- The 5-year median for Non Operating Investment Income is -$4213.5 (2022), against an average of $19.5 billion.
- The sharpest annual moves came in 2023 and 2024: Non Operating Investment Income plunged 2590.3% in 2023, then surged 556322350.03% in 2024.
- Grown Rogue International's Non Operating Investment Income stood at -$140783.0 in 2021, then jumped by 95.56% to -$6250.0 in 2022, then plunged by 1303.18% to -$87699.0 in 2023, then soared by 556322350.03% to $487.9 billion in 2024, then plunged by 51.95% to $234.4 billion in 2025.
- Business Quant data shows GRUSF's Non Operating Investment Income at $234.4 billion in Q3 2025, $79627.0 in Q1 2025, and $487.9 billion in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.05 Bn | 43.08 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.39 Bn | 39.74 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.78 Bn | 22.99 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.92 Bn | 11.39 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 9.99 Bn | - | - |
| 10 | Grown Rogue International | 116.22 Mn | 104.68 Mn | 5.37 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 234.44 Bn |
| Sep 30, 2025 | 234.44 Bn |
| Mar 31, 2025 | 79,627.00 |
| Mar 31, 2025 | 79,627.00 |
| Dec 31, 2024 | 487.89 Bn |
| Dec 31, 2024 | 487.89 Bn |
| Sep 30, 2024 | -487.89 Bn |
| Sep 30, 2024 | -487.89 Bn |
| Mar 31, 2024 | -2,177.00 |
| Mar 31, 2024 | -2,177.00 |
| Dec 31, 2023 | -87,699.00 |
| Dec 31, 2023 | -87,699.00 |
| Jan 31, 2023 | -168,144.00 |
| Jan 31, 2023 | -168,144.00 |
| Jan 31, 2022 | -6,250.00 |
| Jan 31, 2022 | -6,250.00 |
| Oct 31, 2021 | -140,783.00 |
| Oct 31, 2021 | -140,783.00 |
| Jul 31, 2021 | -422,867.00 |
| Jul 31, 2021 | -422,867.00 |